Lu Wentian, Liu Zhichun, Xue Leixi
Department of Rheumatology and Immunology, The Second Affiliated Hospital of Soochow University, Suzhou, CHN.
Cureus. 2022 Apr 29;14(4):e24586. doi: 10.7759/cureus.24586. eCollection 2022 Apr.
Iguratimod has been used in the treatment of rheumatoid arthritis and Sjogren's syndrome (SS). Herein, we report two cases of skin allergic reactions caused by iguratimod in our hospital. Case 1 was a woman with SS who developed diffuse pruritus erythema after three weeks of combination therapy of hydroxychloroquine (HCQ) and iguratimod. When the patient was again prescribed iguratimod after the rash subsided, the pruritus erythema reappeared. Case 2 was a 23-year-old girl treated with prednisone, HCQ, and mycophenolate mofetil for systemic lupus erythematosus and SS. In the follow-up treatment, mycophenolate mofetil was replaced by iguratimod. On the 20th day of treatment, a pruritic erythematous maculopapular rash appeared. To the best of our knowledge, this is the first study to report the characteristics of an allergic rash caused by iguratimod. It is better to administer HCQ and iguratimod successively rather than simultaneously to a patient.
艾拉莫德已用于治疗类风湿关节炎和干燥综合征(SS)。在此,我们报告我院两例由艾拉莫德引起的皮肤过敏反应病例。病例1是一名患有干燥综合征的女性,在接受羟氯喹(HCQ)和艾拉莫德联合治疗三周后出现弥漫性瘙痒性红斑。皮疹消退后,当患者再次服用艾拉莫德时,瘙痒性红斑再次出现。病例2是一名23岁女孩,因系统性红斑狼疮和干燥综合征接受泼尼松、羟氯喹和霉酚酸酯治疗。在后续治疗中,霉酚酸酯被艾拉莫德替代。治疗第20天时,出现瘙痒性红斑丘疹皮疹。据我们所知,这是第一项报告艾拉莫德引起的过敏性皮疹特征的研究。对于患者,最好先后而非同时给予羟氯喹和艾拉莫德。